Newsroom

The focus will be on the well-being of patients and protection of their privacy. The new Helmholtz Medical Security, Privacy and AI Research Center (HMSP) brings together researchers from the fields of IT security, data protection, artificial intelligence and medicine. Together they will develop solutions for individualised medicine, among other projects.

The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), and the University of Queensland’s (UQ) Community for Open Antimicrobial Drug Discovery (CO-ADD) in its efforts to develop and ensure new antibiotics are globally available to all patients who need them. The agreement allows GARDP to access and test Calibr’s ReFRAME compound library and HIPS natural products library. Both libraries will be screened by CO-ADD to discover novel compounds or combinations of drugs that will kill the priority pathogens identified by the WHO in critical need for research and development of new antibiotics.

Am Helmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS) findet am 27. und 28. Juni zum neunten Mal das HIPS-Symposium statt. In diesem Rahmen wird gleichzeitig das 10-jährige Jubiläum des Saarbrücker Standortes des Helmholtz-Zentrums für Infektionsforschung (HZI) in Braunschweig gefeiert. Der Ministerpräsident des Saarlandes, Tobias Hans, die Ministerialdirektorin des Bundesministeriums für Bildung und Forschung, Prof. Veronika von Messling, sowie Prof. Otmar D. Wiestler, Präsident der Helmholtz-Gemeinschaft, Prof. Dirk Heinz, wissenschaftlicher Geschäftsführer des Helmholtz-Zentrums für Infektionsforschung, und Prof. Manfred Schmitt, Präsident der Universität des Saarlandes, werden neben Prof. Rolf Müller, dem geschäftsführenden Direktor des HIPS, die Jubiläumsgäste begrüßen. Neben international renommierten Forschern aus dem Bereich der Wirkstoffforschung präsentieren auch Nachwuchswissenschaftler ihre Ergebnisse.

Medically relevant compounds can often be found in nature. To make them suitable for drugs, they need to be isolated from their natural sources. If sufficient quantities of the agent cannot be isolated in that manner, chemical synthesis comes into play. Without chemical synthesis, many agents were not available for the industrial production of drugs. Phil S. Baran of the Scripps Research Institute in La Jolla, USA, aims to develop the “perfect synthesis”. His methods and reagents are applied in fundamental chemical research and in the production of pharmaceuticals. They are commercially marketed with much success. In honour of his outstanding achievements, he is being awarded the Inhoffen Medal by the “Friends of the HZI”, the sponsors' association of the Helmholtz Centre for Infection Research (HZI).

An increasing number of bacteria are developing resistance to commonly used antibiotics, making it imperative to advance research into new antibiotics for clinical and medical use. Olga Kalinina, the new endowed professor for substance bioinformatics, is dedicating herself to this task. Since January this year, the scientist has been based at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), a branch site of the Helmholtz Centre for Infection Research (HZI) and the Saarland University, working on developing new antibiotics from biologically active natural substances. Her research will be supported until 2022 by the Klaus Faber Foundation in Saarbrücken, with a total of 1.6 million euros.

The treatment of hepatitis C has been based on specific effective antiviral medications for a number of years. Since future development of resistance cannot be ruled out, alternative treatment options are being researched as well. So-called cell entry inhibitors are considered to be promising candidates. In combined efforts with colleagues from the Leibniz University Hannover, scientists from the Helmholtz Centre for Infection Research (HZI) and the TWINCORE pinpointed the target site on the virus and developed improved drug candidates. Their study has recently been published in the Journal of Hepatology.